<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1.</segment>
<segment id="2" parent="1002" relname="preparation">Introduction</segment>
<segment id="3" parent="1004" relname="joint">Primary liver cancer is the sixth most prevalent cancer and the second leading cause of cancer mortality worldwide .</segment>
<segment id="4" parent="1006" relname="span">The most common primary liver cancer is hepatocellular carcinoma</segment>
<segment id="5" parent="4" relname="restatement">( HCC ) ,</segment>
<segment id="6" parent="1006" relname="elaboration">which accounts for &gt;85 % of all cases .</segment>
<segment id="7" parent="1008" relname="span">HCC predominantly arises in the setting of cirrhosis</segment>
<segment id="8" parent="7" relname="elaboration">associated with hepatitis B and C virus infections , alcohol abuse , non-alcoholic steatohepatitis and metabolic diseases .</segment>
<segment id="9" parent="1009" relname="contrast">Early-stage HCC patients are often subjected to surgical resection and liver transplantation .</segment>
<segment id="10" parent="1011" relname="joint">However , 5-year recurrence rates after resection reach &gt;70 %</segment>
<segment id="11" parent="1011" relname="joint">and the efficiency of transplantation is limited by organ shortage and technical issues .</segment>
<segment id="12" parent="13" relname="concession">Although local ablation and transarterial chemoembolization respectively confer 5-year survival rates of 50 â€“ 70 % and survival benefit of &gt;6 months ,</segment>
<segment id="13" parent="1013" relname="span">they are confined to patients with single tumors or multinodular tumors with good liver reserve .</segment>
<segment id="14" parent="1015" relname="span">Chemotherapy is not routinely used due to the chemoresistant character of HCC .</segment>
<segment id="15" parent="1016" relname="span">For advanced HCC , sorafenib , a multi-tyrosine kinase inhibitor</segment>
<segment id="16" parent="15" relname="elaboration">( MTKI ) ,</segment>
<segment id="17" parent="1017" relname="span">has been the only approved systemic first-line agent for over a decade ,</segment>
<segment id="18" parent="17" relname="circumstance">until lenvatinib , another MTKI , recently came into play .</segment>
<segment id="19" parent="1002" relname="joint">Yet , their clinical efficacy was suboptimal , with only ~3 months of prolonged survival .</segment>
<segment id="20" parent="1021" relname="span">Second-line treatments include regorafenib and cabozantinib , also MTKIs ;</segment>
<segment id="21" parent="1023" relname="span">nivolumab and pembrolizumab , immune checkpoint inhibitors</segment>
<segment id="22" parent="1024" relname="span">targeting programmed death-1</segment>
<segment id="23" parent="22" relname="restatement">( PD-1 ) ;</segment>
<segment id="24" parent="1027" relname="span">and ramucirumab , the first biomarker-driven therapeutics</segment>
<segment id="25" parent="24" relname="elaboration">approved for HCC</segment>
<segment id="26" parent="1028" relname="span">that targets the angiogenic vascular endothelial growth factor receptor</segment>
<segment id="27" parent="26" relname="restatement">( VEGFR ) ,</segment>
<segment id="28" parent="1029" relname="joint">all of which have not been established until the past few years</segment>
<segment id="29" parent="1029" relname="joint">and require further investigations .</segment>
<segment id="30" parent="1030" relname="sequence">So far , treatment outcomes for HCC are far from satisfactory ,</segment>
<segment id="31" parent="1031" relname="span">with a 5-year survival rate of only ~18 % .</segment>
<segment id="32" parent="1033" relname="span">Evidently , there is an urgent need</segment>
<segment id="33" parent="32" relname="purpose">to develop more effective therapeutic strategies in HCC .</segment>
<segment id="34" parent="1037" relname="span">Signal transducer and activator of transcription 3</segment>
<segment id="35" parent="34" relname="restatement">( STAT3 )</segment>
<segment id="36" parent="1036" relname="same_unit">has recently emerged as a potential therapeutic target for HCC</segment>
<segment id="37" parent="1036" relname="cause">due to its crucial roles in oncogenesis .</segment>
<segment id="38" parent="1040" relname="span">STAT3 was initially determined to control acute-phase genes in response to interleukin-6</segment>
<segment id="39" parent="38" relname="elaboration">( IL-6 )</segment>
<segment id="40" parent="1042" relname="span">and epidermal growth factor</segment>
<segment id="41" parent="40" relname="restatement">( EGF )</segment>
<segment id="42" parent="1041" relname="same_unit">during inflammation .</segment>
<segment id="43" parent="1044" relname="span">It belongs to the STAT family of cytoplasmic transcription factors</segment>
<segment id="44" parent="43" relname="elaboration">that mediate signal transduction from the plasma membrane to the nucleus in various cellular activities .</segment>
<segment id="45" parent="1046" relname="preparation">The STAT family comprises seven members :</segment>
<segment id="46" parent="1046" relname="span">STAT1 , 2 , 3 , 4 , 5a , 5b and 6 .</segment>
<segment id="47" parent="1049" relname="span">Each of them consists of ( i ) an N-terminal domain for oligomerization ,</segment>
<segment id="48" parent="1050" relname="span">( ii ) a coiled-coil domain</segment>
<segment id="49" parent="48" relname="elaboration">for interaction with regulatory proteins ,</segment>
<segment id="50" parent="1051" relname="span">( iii ) a DNA-binding domain for recognition of specific DNA sequences ,</segment>
<segment id="51" parent="1052" relname="span">( iv ) a Src homology-2</segment>
<segment id="52" parent="51" relname="restatement">( SH2 )</segment>
<segment id="53" parent="1053" relname="span">domain</segment>
<segment id="54" parent="1054" relname="span">that triggers phosphorylation and dimerization</segment>
<segment id="55" parent="1055" relname="joint">after docking to phosphorylated receptors</segment>
<segment id="56" parent="1056" relname="span">and ( iv ) a C-terminal transactivation domain with specific tyrosine ( Y )</segment>
<segment id="57" parent="1058" relname="span">( present in all STATs ) and serine ( S ) residues</segment>
<segment id="58" parent="57" relname="elaboration">( absent in STAT2 and 6 )</segment>
<segment id="59" parent="1058" relname="elaboration">that are phosphorylated upon transcriptional activation .</segment>
<segment id="60" parent="1060" relname="span">Intensive investigation has been done on STAT3 since its discovery ,</segment>
<segment id="61" parent="60" relname="elaboration">revealing its physiological roles in early embryonic development , growth and differentiation of various adult tissues .</segment>
<segment id="62" parent="1002" relname="joint">In addition , its pathogenic roles in cancer initiation , progression , metastasis , chemoresistance and immunoevasion have been uncovered .</segment>
<segment id="63" parent="1002" relname="joint">To date , STAT3 is widely recognized as an oncogenic factor in diverse human cancers .</segment>
<segment id="64" parent="1063" relname="span">Therefore , targeting STAT3 might be an attractive therapeutic strategy for HCC treatment .</segment>
<segment id="65" parent="64" relname="evaluation">In this review , we summarize the oncogenic roles of STAT3 in HCC and the current clinical development of STAT3-targeted therapeutics .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="joint"/>
<group id="1004" type="multinuc" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="joint"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1007" type="span" parent="1004" relname="elaboration"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="multinuc" parent="1008" relname="elaboration"/>
<group id="1010" type="span" parent="1009" relname="contrast"/>
<group id="1011" type="multinuc" parent="1010" relname="span"/>
<group id="1012" type="span" parent="1011" relname="elaboration"/>
<group id="1013" type="span" parent="1012" relname="span"/>
<group id="1014" type="span" parent="1013" relname="elaboration"/>
<group id="1015" type="span" parent="1017" relname="concession"/>
<group id="1016" type="span" parent="14" relname="elaboration"/>
<group id="1017" type="span" parent="1014" relname="span"/>
<group id="1021" type="span" parent="1002" relname="joint"/>
<group id="1022" type="multinuc" parent="20" relname="elaboration"/>
<group id="1023" type="span" parent="1022" relname="joint"/>
<group id="1024" type="span" parent="21" relname="elaboration"/>
<group id="1025" type="span" parent="1022" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="span"/>
<group id="1027" type="span" parent="1026" relname="span"/>
<group id="1028" type="span" parent="1027" relname="elaboration"/>
<group id="1029" type="multinuc" parent="1026" relname="elaboration"/>
<group id="1030" type="multinuc" parent="1002" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="sequence"/>
<group id="1032" type="multinuc" parent="31" relname="elaboration"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="multinuc" parent="1032" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="span"/>
<group id="1037" type="span" parent="1036" relname="same_unit"/>
<group id="1038" type="multinuc" parent="1034" relname="joint"/>
<group id="1039" type="multinuc" parent="1038" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1041" type="multinuc" parent="1039" relname="same_unit"/>
<group id="1042" type="span" parent="1041" relname="same_unit"/>
<group id="1043" type="span" parent="1038" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="1044" relname="elaboration"/>
<group id="1046" type="span" parent="1045" relname="span"/>
<group id="1047" type="multinuc" parent="46" relname="elaboration"/>
<group id="1048" type="span" parent="1047" relname="same_unit"/>
<group id="1049" type="span" parent="1048" relname="span"/>
<group id="1050" type="span" parent="47" relname="elaboration"/>
<group id="1051" type="span" parent="1049" relname="restatement"/>
<group id="1052" type="span" parent="50" relname="restatement"/>
<group id="1053" type="span" parent="1047" relname="same_unit"/>
<group id="1054" type="span" parent="53" relname="elaboration"/>
<group id="1055" type="multinuc" parent="54" relname="circumstance"/>
<group id="1056" type="span" parent="1055" relname="joint"/>
<group id="1057" type="span" parent="56" relname="elaboration"/>
<group id="1058" type="span" parent="1057" relname="span"/>
<group id="1060" type="span" parent="1002" relname="joint"/>
<group id="1063" type="span" parent="1002" relname="joint"/>
	</body>
</rst>
